Exploring imaging and tumor environment relationships in liver cancer
Exploring the Association of Imaging and Tumor Microenvironment in Liver Cancer Using Radiogenomic Approach（Radiogenomics-Liver）
This study is trying to see how imaging results relate to the tumor environment in liver cancer patients to better understand their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06536998 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to investigate how imaging data correlates with the tumor microenvironment in liver cancer patients and how these factors influence patient prognosis. The study will involve patients treated at Wuhan Union Hospital who have undergone imaging scans prior to treatment. By analyzing the relationship between imaging characteristics and tumor biology, the research seeks to enhance understanding of liver cancer progression and outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who have been treated for liver cancer and have undergone at least one CT or MRI scan prior to treatment.
Not a fit: Patients with poor image quality, incomplete clinical data, or other primary malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic tools and personalized treatment strategies for liver cancer patients.
How similar studies have performed: While the specific approach of radiogenomics in liver cancer is relatively novel, similar studies in other cancers have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients treated for liver cancer in Wuhan Union Hospital from August 2024 to August 2027; 2. Aged \> 18 years old; 3. At least one CT scan or MRI scan before treatment; 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors. Exclusion criteria： 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignancy other than liver cancer; 4. Unclear pathological diagnosis.
Where this trial is running
Wuhan, Hubei
- Union Hospital，Tongji Medical College，Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: Lian Yang
- Email: yanglian@hust.edu.cn
- Phone: 18986273791
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.